All In MedTech

Device Trial Radar · NCT04774640

Development of a NIPTT for Detecting Copy Number Variations

Noninvasive In Vitro Diagnostic Test For Fetal Chromosomal Abnormality: Assay Development and Optimization in Affected Pregnancies With Abnormal Microarray Findings

Last checked: Nov 19, 2026Latest source record: Aug 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

9

Actual

Start

May 29, 2014

Primary completion

Apr 30, 2018

Study completion Apr 30, 2018

Sponsor

Lead sponsor
Sequenom, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Columbia University
First posted
Mar 1, 2021

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
Female only, from 18 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To collect whole blood samples from pregnant women for the purpose of developing, optimizing and evaluating laboratory-developed noninvasive prenatal test (NIPT) for the detection of fetal chromosomal abnormalities of interest defined as microinsertions, microdeletions and other copy number variations (CNVs). The NIPT result will be compared to the test results obtained by microarray analysis of fetal cellular material obtained by amniocentesis or chorionic villus sampling.

Conditions

  • Copy Number Variations

Interventions

  • MaterniT GENOMEDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Development of non-invasive pregnancy test (NIPT)Time frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Columbia University

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.